<DOC>
	<DOCNO>NCT00017654</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effect supplementation donor T-cell deplete , CD34+ peripheral blood stem cell durable engraftment incidence graft-versus-host disease patient aplastic anemia undergo allogeneic bone marrow transplantation .</brief_summary>
	<brief_title>Study Allogeneic Bone Marrow T-Cell Depleted , CD34+ Peripheral Blood Stem Cell Transplantation Patients With Aplastic Anemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Bone marrow peripheral blood stem cell ( PBSC ) harvest HLA identical 1 antigen mismatch related donor . PBSC select CD34+ cell T cell deplete . Patients receive cyclophosphamide IV 2 hour day -6 -3 anti-thymocyte globulin IV methylprednisolone IV 10-12 hour day -5 -3 . T-cell deplete PBSC bone marrow infuse day 0 . Patients receive cyclosporine IV 12-24 hour day -1 120 follow taper methylprednisolone IV day 7-64 graft-versus-host disease prophylaxis . Patients follow every 30 day 1 year , every 60 day 2 year , need minimum 3 year .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis lifethreatening transfusiondependent marrow immunemediated failure involve one hematopoietic cell line evidence one following : Granulocyte count le 500/mm3 Platelet count le 20,000/mm3 Absolute reticulocyte count le 60,000/mm3 Immunemediated anemia and/or thrombocytopenia must fail corticosteroid cyclosporine Paroxysmal nocturnal hemoglobinuria progressive marrow failure allow Either congenital acquire severe granulocytopenia history life threaten infection No diagnosis Fanconi 's anemia HLA identical 1 antigen mismatch related donor meeting follow criterion : No prior concurrent malignancy except localize basal cell squamous cell skin cancer ( malignancy judge cure local surgery , head neck cancer stage I breast cancer , consider individual basis ) Negative pregnancy test Patient Characteristics Hepatic : Hepatitis B surface antigen negative Bilirubin great 2.0 mg/dL Transaminases great 2 time upper limit normal ( absence Gilbert 's disease ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No history coronary artery disease LVEF least 40 % MUGA Pulmonary : FEV1 least 50 % predict FVC least 50 % predict DLCO least 50 % predict Other : No uncontrolled diabetes mellitus No illness would preclude aggressive chemotherapy No prior concurrent malignancy except localize basal cell squamous cell skin cancer ( malignancy judge cure local surgery , head neck cancer stage I breast cancer , consider individual basis ) No psychiatric illness mental deficiency would preclude study Not pregnant nursing Fertile patient must use effective contraception HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>aplastic anemia</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>